Role of ischemia-modified albumin in estimating the extent and scope of cardiac ischemia in patients with ST elevation myocardial infarction
Abstract
Ischemia-modified albumin (IMA) is a laboratory biomarker of cardiac ischemia. Our study aims to determine whether IMA can estimate or represent to any degree the extent of myocardial ischemia.
We expect that the higher the marker of cardiac necrosis (maximum value after serial measurements) the greater the preceding cardiac ischemia, indicated by IMA in patients diagnosed with STEMI prior to direct percutaneous coronary intervention (PCI). We studied 216 patients indicated for direct PCI with a diagnosis of ST elevation myocardial infarction.We observed that there was no significant association between increase in IMA and CK-MB (R2 = 0.011, p = 0.637).
Similar results were noted in the case of cardiac troponin T (cTnT) (R2 = 0.0068, p = 0.483). We concluded that IMA does not provede information regarding the extent and scope of cardiac ischemia in patients with STEMI.